Fidelis Capital Partners LLC Has $1.83 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Fidelis Capital Partners LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,074 shares of the medical research company’s stock after selling 197 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,829,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. CBIZ Investment Advisory Services LLC increased its stake in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at about $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $31,000. DiNuzzo Private Wealth Inc. lifted its holdings in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after buying an additional 45 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TMO shares. Wells Fargo & Company raised their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a report on Wednesday, October 8th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Finally, TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $601.65.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 36,420 shares of company stock worth $19,980,884. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 1.2%

Shares of Thermo Fisher Scientific stock opened at $572.72 on Monday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company’s fifty day simple moving average is $518.58 and its 200-day simple moving average is $462.80. The company has a market cap of $215.18 billion, a price-to-earnings ratio of 33.09, a PEG ratio of 3.27 and a beta of 0.82. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the firm earned $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.